In melanomas, MITF targets a number of genes with antagonistic behaviors, including genes such as CDK2 and Bcl-2, which promote cell cycle progression and survival, as well as p21CIP1 and p16INK4A, which halt the cell cycle [43,143-145]. This evidence concerns the gene BCL2 and melanoma.